Arformoterol Tartrate Solution
Product Images NDC 62756-277

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate (NDC 62756-277). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-arformoterol-carton (Spl Arformoterol Carton)

Spl-arformoterol-carton (Spl Arformoterol Carton)
Arformoterol Tartrate Inhalation Solution is a medication available in 2ml vials. Each vial contains 15mg of arformoterol, equivalent to 22mg of arformoterol tartrate in a sterile saline solution. The pH of the solution is adjusted to 5.0 with citric acid and sodium citrate. The medication is to be protected from light and excessive heat. Unopened vials can be stored in a fridge or at room temperature for up to six weeks, but it should not be used past the expiry date or after six weeks of storage at room temperature, whichever is sooner. The medication is for oral inhalation only, and should only be used as directed by a physician. It should not be used by children, and it does not come in a child-resistant package. Additional information for patients is available on the Sun Pharmaceutical Industries website, and the medication is distributed by the same company. The medication is made in India by Sun Pharmaceutical Medicare Limited.*
FDA Label Image

Spl-arformoterol-chem-str (Spl Arformoterol Chem Stru)

FDA Label Image

Spl-arformoterol-figure-1 (Spl Arformoterol Figure 1)

Spl-arformoterol-figure-1 (Spl Arformoterol Figure 1)
The figure shows the mean change in FEV1 (forced expiratory volume in 1 second) over time, specifically at Week 0 or Day 1, for Clinical Trial A. The x-axis indicates the hours post-dose, while the y-axis represents the mean change from baseline FEV1. The ITT (intent-to-treat) population for the placebo group has a sample size of 143, with a baseline FEV1 of 120 L. Meanwhile, the experimental group, which received St BD (T a-141) via atomenteral (inhalation) route, has a sample size of not provided, with a baseline FEV1 of 115 L.*
FDA Label Image

Spl-arformoterol-figure 2 (Spl Arformoterol Figure 2)

FDA Label Image

Spl-arformoterol-ifu-fig-1 (Spl Arformoterol Ifu Fig 1)

FDA Label Image

Spl-arformoterol-ifu-fig-2 (Spl Arformoterol Ifu Fig 2)

FDA Label Image

Spl-arformoterol-ifu-fig-3-4 (Spl Arformoterol Ifu Fig 3 4)

Spl-arformoterol-ifu-fig-3-4 (Spl Arformoterol Ifu Fig 3 4)
This is a description of a product called "FACE MASK". The text does not provide any further details about the product, such as its purpose, features, or specifications. The text also includes references to "Figure 3" and "Figure 4" which may be illustrations or diagrams related to the product, but without access to those images, their content cannot be determined.*
FDA Label Image

Spl-arformoterol-ifu-fig-5 (Spl Arformoterol Ifu Fig 5)

FDA Label Image

Spl-arformoterol-ifu-fig-6 (Spl Arformoterol Ifu Fig 6)

FDA Label Image

Spl-arformoterol-label (Spl Arformoterol Label)

Spl-arformoterol-label (Spl Arformoterol Label)
Arformoterol Tartrate Inhalation Solution is an oral inhalation treatment that comes in 5 packs, each containing 2ml sterile unit-dose vials. Each vial holds 15 mcg of arformoterol, which is equivalent to 22 mcg arformoterol tartrate. This medication is stored in a foil pouch and users should return it to the pouch after use. The unit-dose vial should not be reused, as it only contains a single dose. It is important to keep out of reach of children and to protect from light and excessive heat. The medication can be stored in the refrigerator or at room temperature. This medication should be used as directed by a physician, and users should not exceed the recommended dosage. The expiration date should always be checked and the solution discarded if it is not colorless. Additional patient information is available on the manufacturers' website.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.